3 Class 1 New Drugs Approved Clinically from Heng Rui, Reding...

On July 16, Novartis QBW251, Reding ZL-1201 Injection and Hengrui Injection SHR-1806 were approved for clinical use in bronchodilator, advanced solid tumor or malignant blood tumor and advanced malignant tumor, respectively1Novartis QBW251 QBW251 is a CFTR enhancer, and Novartis' proposed indications include cystic fibrosis and chronic obstructive pulmonary disease2The ZL-1201 re-ding ZL-1201 is a CD47 monoantigen, CD47 also known as integrator-related protein (IAP), is one of the hot targets in the field of tumor immunotherapyCD47 is widely expressed in normal cells, mediated by apoptosis, proliferation, immunity and a series of reactions, CD47 is highly expressed on the surface of tumor cells, can be combined with the signal-regulating protein alpha (SIRP alpha) on the surface of macrophages, to the macrophage to send a "Don't eat me" signal to escape the body's immune system attackPharmaceutical Rubik's Cube NextPharma database shows that there is currently no global target for the target of new drugs approved for the market, the fast-moving enterprises for Gilead (magrolimab), domestic development manufacturers have Sky mirror biology and Cinda biology and so on3Hengrui SHR-1806 Hennessy's SHR-1806 is an OX-40 monogenic, OX40 and its ligand OX40L belong to the TNF/TNFR super family of positive co-stimulating molecules, OX40/OX40L interaction in inflammatory diseases, autoimmune diseases, tumors and transplant immunity, the occurrence and development of very important roleAccording to the Pharmaceutical Cube NextPharma database, there are no new drugs approved for the target worldwide, and the fastest-moving companies are Roche (pogalizumab), AstraZeneca and Pfizer (PF-04518600), while the fastest-growing companies in China are Cinda (IBI101), Baiji Shenzhou (BGB-A445) and Liju Pharmaceuticals (all-person anti-OX40)